| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -52,388 | -34,808 |
| Accretion of discounts on marketable securities | 2,268 | 1,533 |
| Depreciation and amortization | 685 | 480 |
| Stock-based compensation expense | 14,214 | 9,185 |
| Non-cash operating lease expense | 1,646 | 1,168 |
| Prepaid expenses and other assets | 1,177 | 1,615 |
| Accounts payable, accrued expenses and other current liabilities | 237 | -91 |
| License fees payable | -35,000 | -35,000 |
| Operating lease liabilities | -2,092 | -1,471 |
| Net cash used in operating activities | -76,143 | -63,685 |
| Purchase of marketable securities | 186,395 | 138,652 |
| Proceeds from maturities of marketable securities | 130,619 | 74,410 |
| Purchase of property and equipment | 83 | 83 |
| Net cash (used in) provided by investing activities | -55,859 | -64,325 |
| Proceeds from issuances of common stock in 'at-the-market' offerings, net of issuance costs | 0 | 0 |
| Proceeds from issuance of common stock under employee stock plans | 197 | 161 |
| Net cash provided by financing activities | 197 | 161 |
| Net decrease in cash and cash equivalents | -131,805 | -127,849 |
| Cash and cash equivalents at beginning of period | 169,735 | - |
| Cash and cash equivalents at end of period | 37,930 | - |
RAPT Therapeutics, Inc. (RAPT)
RAPT Therapeutics, Inc. (RAPT)